Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TET3 | O43151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.48 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.48 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.48 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8747202 | 0.93 | CYP3A4 (0.54) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL4811633 | 0.93 | CYP3A4 (0.57) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL4807202 | 0.91 | CYP3A4 (0.56) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A | |
| SCHEMBL11046813 | 0.88 | POLB (0.56) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL301027 | 0.83 | KMT2A (0.64) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL12170296 | 0.83 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL837139 | 0.81 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL1480336 | 0.81 | LMNA (0.55) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL4436345 | 0.81 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 | |
| SCHEMBL13545164 | 0.79 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-05 | — | — | US | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-20140005232-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| EP-2057164-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008021781-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | ALDH1A1 2912/4885SMN1; SMN2 4495/4885CYP3A4 1563/4885 |
| US-20140186469-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PIK3C3, PRKDC, PIK3CD | ALDH1A1 2948/4885SMN1; SMN2 4449/4885CYP3A4 4109/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | ALDH1A1 3710/4885SMN1; SMN2 4663/4885CYP3A4 470/4885 |
| US-20140005232-A1 | PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES | PDPK1, MTOR, PIK3C2A | ALDH1A1 2536/4885SMN1; SMN2 1614/4885CYP3A4 4189/4885 |
| US-20150065500-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | ALDH1A1 1786/4885SMN1; SMN2 4779/4885CYP3A4 1164/4885 |
| US-20240307394-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS | MRGPRX1, MRGPRX4, MRGPRX2 | ALDH1A1 3659/4885SMN1; SMN2 4666/4885CYP3A4 2453/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | ALDH1A1 1680/4885SMN1; SMN2 4701/4885CYP3A4 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.